Todd E.  Simpson net worth and biography

Todd Simpson Biography and Net Worth

CFO of Seagen
Todd brings extensive financial leadership experience, most notably at public biotechnology companies, to Seagen. Leveraging this expertise, he has positioned our finance, investor relations, communications and facilities teams to support the company’s mission and continued growth.

Prior to joining Seagen, Todd was the Vice President of Finance and Administration and Chief Financial Officer at both Targeted Genetics and Aastrom Biosciences (now Vericel Corporation). He also held positions at Integra LifeSciences Corporation and Telios Pharmaceuticals, Inc. Todd began his career at Ernst & Young LLP in the life sciences and technology practices.

Todd holds a B.S. in Accounting and Computer Science from Oregon State University. He is also the Chairman of the Board for Neoleukin Therapeutics, Inc.

What is Todd E. Simpson's net worth?

The estimated net worth of Todd E. Simpson is at least $29.46 million as of August 31st, 2023. Mr. Simpson owns 128,803 shares of Seagen stock worth more than $29,462,398 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Simpson may own. Additionally, Mr. Simpson receives a salary of $1,260,000.00 as CFO at Seagen. Learn More about Todd E. Simpson's net worth.

How old is Todd E. Simpson?

Mr. Simpson is currently 62 years old. There are 4 older executives and no younger executives at Seagen. The oldest executive at Seagen is Dr. Roger D. Dansey M.D., Chief Medical Officer and President of Research & Development, who is 67 years old. Learn More on Todd E. Simpson's age.

What is Todd E. Simpson's salary?

As the CFO of Seagen Inc., Mr. Simpson earns $1,260,000.00 per year. There are 2 executives that earn more than Mr. Simpson. The highest earning executive at Seagen is Dr. Roger D. Dansey M.D., Chief Medical Officer and President of Research & Development, who commands a salary of $2,480,000.00 per year. Learn More on Todd E. Simpson's salary.

How do I contact Todd E. Simpson?

The corporate mailing address for Mr. Simpson and other Seagen executives is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. Seagen can also be reached via phone at (425) 527-4000 and via email at [email protected]. Learn More on Todd E. Simpson's contact information.

Has Todd E. Simpson been buying or selling shares of Seagen?

Todd E. Simpson has not been actively trading shares of Seagen in the last ninety days. Most recently, Todd E. Simpson sold 2,122 shares of the business's stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $206.97, for a transaction totalling $439,190.34. Following the completion of the sale, the chief financial officer now directly owns 128,803 shares of the company's stock, valued at $26,658,356.91. Learn More on Todd E. Simpson's trading history.

Who are Seagen's active insiders?

Seagen's insider roster includes Roger Dansey (Insider), David Epstein (CEO), David Gryska (Director), Vaughn Himes (Insider), Marc Lippman (Director), Jean Liu (EVP), Charles Romp (EVP), Clay Siegall (CEO), Todd Simpson (CFO), and Daniel Welch (Director). Learn More on Seagen's active insiders.

Todd E. Simpson Insider Trading History at Seagen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/31/2023Sell2,122$206.97$439,190.34128,803View SEC Filing Icon  
8/29/2023Sell485$206.00$99,910.00130,925View SEC Filing Icon  
4/10/2023Sell55,344$204.58$11,322,275.52118,946View SEC Filing Icon  
4/6/2023Sell243$205.86$50,023.98118,946View SEC Filing Icon  
3/9/2023Sell42,793$176.61$7,557,671.73117,185View SEC Filing Icon  
2/27/2023Sell20,000$182.53$3,650,600.00117,185View SEC Filing Icon  
2/16/2023Sell39,946$160.00$6,391,360.00137,185View SEC Filing Icon  
8/16/2022Sell1,967$170.22$334,822.74141,371View SEC Filing Icon  
4/20/2022Sell567$144.32$81,829.44127,891View SEC Filing Icon  
11/3/2021Sell40,232$185.00$7,442,920.00View SEC Filing Icon  
10/29/2021Sell33,564$180.00$6,041,520.00View SEC Filing Icon  
8/31/2021Sell3,987$167.52$667,902.24View SEC Filing Icon  
8/16/2021Sell533$154.55$82,375.15View SEC Filing Icon  
12/18/2020Sell33,669$200.00$6,733,800.00View SEC Filing Icon  
11/5/2020Sell7,509$180.37$1,354,398.33View SEC Filing Icon  
8/31/2020Sell4,187$155.69$651,874.03View SEC Filing Icon  
8/18/2020Sell9,262$158.17$1,464,970.54View SEC Filing Icon  
8/3/2020Sell20,000$165.72$3,314,400.00View SEC Filing Icon  
7/1/2020Sell11,573$167.58$1,939,403.34View SEC Filing Icon  
5/5/2020Sell26,867$162.94$4,377,708.98175,863View SEC Filing Icon  
9/30/2019Sell15,000$85.00$1,275,000.00View SEC Filing Icon  
8/28/2019Sell5,909$73.21$432,597.89View SEC Filing Icon  
8/20/2019Sell12,500$80.00$1,000,000.00View SEC Filing Icon  
4/5/2019Sell12,500$78.00$975,000.00View SEC Filing Icon  
3/4/2019Sell10,000$75.00$750,000.00View SEC Filing Icon  
8/27/2018Sell5,427$74.23$402,846.21View SEC Filing Icon  
11/1/2017Sell39,385$60.91$2,398,940.35View SEC Filing Icon  
9/6/2017Sell9,638$52.00$501,176.00View SEC Filing Icon  
8/28/2017Sell4,937$47.89$236,432.93View SEC Filing Icon  
8/20/2015Sell5,825$42.02$244,766.50179,874View SEC Filing Icon  
7/12/2013Sell92,527$37.45$3,465,136.15View SEC Filing Icon  
See Full Table

Todd E. Simpson Buying and Selling Activity at Seagen

This chart shows Todd E Simpson's buying and selling at Seagen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Seagen Company Overview

Seagen logo
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.
Read More

Today's Range

Now: $228.74
Low: $228.74
High: $228.74

50 Day Range

MA: $228.74
Low: $228.74
High: $228.74

2 Week Range

Now: $228.74
Low: $123.77
High: $228.96

Volume

86 shs

Average Volume

1,478,439 shs

Market Capitalization

$42.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32